Posted inCardiology news
Rare but High-Risk: New-Onset RBBB After TAVR Strongly Linked to Pacemaker Need
New-onset right bundle branch block after TAVR is rare but carries a high risk of requiring permanent pacing within one week.
Posted inCardiology news
Prophylactic Pacemakers After TAVR: Low Pacing Burden Raises Questions on Routine Use
One-fourth of TAVR patients receive prophylactic pacemakers, but most have minimal pacing needs at 30 days.
Posted inCardiology news
PROMOTE Study Validates Algorithm for Conduction Disturbance Management After TAVR
A prospective multicenter study confirms that a prespecified algorithm for conduction disturbance management after TAVR is safe, with low sudden cardiac death risk but persistent high pacemaker rates.
Posted inCardiology news
Distinct Mechanisms Drive Early and Delayed Heart Block After TAVR: Insights from Boston Cohort Study
Prospective cohort study reveals AV nodal versus infranodal conduction patterns underpinning timing of heart block after TAVR.
Posted inCardiology Internal Medicine news
Riboflavin and Blood Pressure: Evidence Remains Uncertain Despite Genetic Promise
Cochrane review shows uncertain effects of riboflavin on blood pressure, highlighting a need for larger and better-quality trials.
Posted inCardiology Neurology news
Low-Dose Colchicine Reduces Myocardial Infarction and Stroke Risk in Cardiovascular Disease Patients
A large meta-analysis shows colchicine can lower MI and stroke risk without raising serious adverse events, but GI side effects remain a concern.
Posted inCardiology news
Long-Term Hormone Therapy in Menopausal Women: Balancing Benefits and Risks
Updated Cochrane review shows mixed outcomes for long-term hormone therapy in peri- and postmenopausal women.
Posted inCardiology Neurology news
Beyond the Lesion: Long-Term Cardiovascular, Neurologic, Psychiatric, and Endocrine Risks After Traumatic Spinal Cord Injury
A large retrospective cohort study shows traumatic spinal cord injury (TSCI) is associated with increased long-term cardiovascular, neurologic, psychiatric, and endocrine morbidity and higher mortality, even in previously healthy adults.
Posted inCardiology news Psychiatry
Tailored Digital Emotion Regulation Improves Mental Health in Adults With Congenital Heart Disease: Results of a National Randomized Trial
A 3‑arm randomized trial in 524 adults with congenital heart disease found a 4‑week tailored digital emotion‑regulation program produced moderate improvements in emotion regulation and multiple psychosocial outcomes versus usual care; a general program showed delayed, smaller benefits.
Posted inCardiology Clinical Updates General Surgery news
Prothrombin Complex Concentrate versus Frozen Plasma for Coagulopathic Bleeding in Cardiac Surgery: Evidence Synthesis from the FARES-II Multicenter Randomized Clinical Trial and Related Studies
This review synthesizes evidence demonstrating that 4-factor prothrombin complex concentrate (4F-PCC) offers superior hemostatic efficacy and safety compared to frozen plasma in managing coagulopathic bleeding during cardiac surgery, supported by the recent FARES-II trial and corroborating clinical research.
Posted inCardiology news Pediatrics
Expectant Management Improves Early Survival Without Increasing BPD: Results from the PDA Randomized Clinical Trial
In extremely preterm infants with a protocol-defined PDA, expectant management yielded similar rates of death or BPD at 36 weeks’ postmenstrual age but significantly higher survival compared with active pharmacologic closure.
Posted inCardiology Critical Care news
Conservative vs Liberal Post‑Oxygenator Targets on VA‑ECMO: Feasibility Concerns and No Early Biomarker Benefit in a Pilot RCT
A pilot multicenter RCT comparing conservative vs liberal post-oxygenator oxygen targets during VA-ECMO for cardiogenic shock found the conservative approach difficult to maintain (target achieved 33% of time) and no difference in biomarkers of gut, renal, hepatic injury or inflammation.
Posted inCardiology Neurology news
No Net Benefit from Adding Antiplatelet Therapy to Anticoagulation After Stroke in Patients with Atrial Fibrillation and Atherosclerosis: Results from the ATIS‑NVAF Randomized Trial
In older patients with ischemic stroke/TIA, nonvalvular atrial fibrillation, and atherosclerotic cardiovascular disease, adding a single antiplatelet agent to anticoagulation did not reduce ischemic events but markedly increased bleeding, providing no net clinical benefit versus anticoagulant monotherapy.
Posted inCardiology Critical Care news
VA‑ECMO Raises Bleeding and Vascular Complications but Does Not Mediate 30‑Day Mortality in Infarct‑Related Cardiogenic Shock
A mediation analysis of the randomized ECLS‑SHOCK trial found that VA‑ECMO increased moderate–severe bleeding and vascular complications but these events did not statistically mediate 30‑day mortality in patients with acute myocardial infarction complicated by cardiogenic shock.
Posted inCardiology Critical Care news
Levosimendan Does Not Shorten Time to VA‑ECMO Weaning in Severe Cardiogenic Shock: Results of the LEVOECMO Randomized Trial
In the LEVOECMO randomized trial (n=205), early levosimendan did not reduce time to successful VA‑ECMO weaning or improve 60‑day mortality versus placebo; ventricular arrhythmias were more frequent with levosimendan.
Posted inCardiology Neurology news
No Net Benefit from Adding Antiplatelet Therapy to Anticoagulation After Ischemic Stroke With Atrial Fibrillation and Atherosclerosis — Higher Bleeding Risk
In a randomized trial of 316 patients with ischemic stroke/TIA, nonvalvular atrial fibrillation, and atherosclerotic disease, adding an antiplatelet to anticoagulation did not reduce ischemic events but doubled clinically relevant bleeding compared with anticoagulant monotherapy.
Posted inCardiology Nephrology news
Lorundrostat Lowers 24‑Hour Systolic Blood Pressure in Treatment‑Resistant Hypertension but Raises Hyperkalemia Concerns
A randomized, placebo‑controlled trial found lorundrostat reduced 24‑hour systolic BP by ~7–8 mm Hg versus placebo in patients with uncontrolled, treatment‑resistant hypertension; notable rates of marked hyperkalemia occurred only in active treatment groups.
Posted inCardiology news
Stepping Down Antihypertensives in Frail Nursing-Home Residents Did Not Reduce Mortality: Results from the RETREAT-FRAIL Trial
In the RETREAT-FRAIL randomized trial of nursing-home residents ≥80 years with systolic BP <130 mm Hg, a protocolized step-down of antihypertensive drugs reduced medication burden and raised systolic BP modestly but did not change all-cause mortality or adverse-event rates over ~3 years.
Posted inCardiology news
Early Aspirin Withdrawal After PCI in ACS: Less Bleeding but Not Clearly Safe — Lessons from the NEO-MINDSET Trial
In patients with acute coronary syndromes treated with PCI, stopping aspirin within 4 days and continuing potent P2Y12 inhibitor monotherapy reduced bleeding but did not meet noninferiority for ischemic events versus 12‑month DAPT; stent thrombosis was numerically higher.
Posted inCardiology news
Stopping Aspirin After 1 Month Post‑PCI in Low‑Risk AMI: P2Y12 Monotherapy Is Noninferior and Bleeding‑Sparing
In low‑risk AMI patients with early complete revascularization and uneventful 1‑month DAPT, P2Y12‑inhibitor monotherapy was noninferior to continued DAPT for ischemic outcomes and substantially reduced clinically relevant bleeding.